Penumbra (NYSE:PEN) (NYSE: PEN) is a global medical device company focused on developing innovative therapies to treat vascular and neurovascular diseases. The company designs, manufactures and markets a range of proprietary products used in interventional procedures, including aspiration systems for ischemic stroke, thrombectomy devices for peripheral arterial and venous occlusions, as well as embolization coils and plugs for hemorrhagic and aneurysm treatment. These offerings are supported by imaging and navigation tools aimed at improving procedural outcomes and patient safety.
Penumbra’s core product lines include the Penumbra System and the Indigo System, which utilize advanced aspiration and clot-retrieval technologies. The Lightning Stroke Platform integrates real-time, multispectral imaging for rapid triage in acute ischemic stroke cases. For peripheral vascular interventions, the company’s portfolio features a suite of access sheaths, catheters and guide wires designed for use in complex anatomies. Penumbra continually invests in R&D to expand its broad pipeline of neurology, peripheral and oncology-focused devices.
Founded in 2004 and headquartered in Alameda, California, Penumbra has built a commercial presence across North America, Europe, Asia-Pacific and Latin America. The company’s distribution network encompasses direct sales teams, strategic partnerships and a growing network of clinical specialists who collaborate with leading hospitals and imaging centers. Penumbra also supports clinical research initiatives worldwide to validate product performance and advance best practices in minimally invasive therapies.
Penumbra is guided by an experienced leadership team with deep expertise in medical technology innovation, regulatory affairs and global commercialization. Under the direction of its chief executive officer, the company remains committed to improving patient outcomes through continuous product enhancement, strategic alliances and rigorous clinical evaluation.
